Payment overview · 2025
General Payments
$322.09
18 reported records · 6 companies
Healthcare provider profile · identity verified
Eric Hames, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT WORTH, TX · NPI 1174917116
Verified facts
What the public records show
CMS Open Payments records show Eric Hames, MD received $322.09 in general payments during 2025 across 18 reported records.
Lilly USA, LLC accounted for 34.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $110.84 | 34.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.57 | 24.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.94 | 21.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.75 | 9.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.65 | 5.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.34 | 5.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $322.09 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $101.28 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.50 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $78.50 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.00 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.75 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.75 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.57 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.34 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
99 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 637 | 207 |
| Amlodipine Besylate | Amlodipine Besylate | 391 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 112 |
| Lisinopril | Lisinopril | 353 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 99 |
| Losartan Potassium | Losartan Potassium | 281 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 93 |
| Omeprazole | Omeprazole | 244 | 87 |
| Gabapentin | Gabapentin | 198 | 71 |
| Meloxicam | Meloxicam | 194 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 52 |
| Metformin Hcl Er | Metformin Hcl | 183 | 61 |
| Metformin Hcl | Metformin Hcl | 175 | 59 |
| Carvedilol | Carvedilol | 155 | 49 |
| Montelukast Sodium | Montelukast Sodium | 155 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 54 |
| Ozempic | Semaglutide | 142 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 44 |
| Sertraline Hcl | Sertraline Hcl | 138 | 44 |
| Trazodone Hcl | Trazodone Hcl | 132 | 47 |
| Furosemide | Furosemide | 125 | 43 |
| Methylprednisolone | Methylprednisolone | 117 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 49 |
| Simvastatin | Simvastatin | 105 | 34 |
| Trulicity | Dulaglutide | 99 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 40 |
| Buspirone Hcl | Buspirone Hcl | 75 | 23 |
| Allopurinol | Allopurinol | 74 | 21 |
| Ezetimibe | Ezetimibe | 73 | 23 |
| Jardiance | Empagliflozin | 72 | 22 |
| Tramadol Hcl | Tramadol Hcl | 72 | 18 |
| Potassium Chloride | Potassium Chloride | 70 | 24 |
| Clonazepam | Clonazepam | 68 | 12 |
| Methocarbamol | Methocarbamol | 67 | 26 |
| Azithromycin | Azithromycin | 64 | 56 |
| Alendronate Sodium | Alendronate Sodium | 61 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 16 |
| Bupropion Xl | Bupropion Hcl | 60 | 19 |
| Eliquis | Apixaban | 59 | 17 |
| Prednisone | Prednisone | 58 | 33 |
| Alprazolam | Alprazolam | 57 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 45 |
| Famotidine | Famotidine | 51 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 18 |
| Glimepiride | Glimepiride | 50 | 15 |
| Fenofibrate | Fenofibrate | 47 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 16 |
| Estradiol | Estradiol | 42 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 13 |
| Spironolactone | Spironolactone | 41 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 40 | 14 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 12 |
| Cephalexin | Cephalexin | 36 | 27 |
| Naproxen | Naproxen | 35 | 15 |
| Ondansetron Odt | Ondansetron | 34 | 24 |
| Celecoxib | Celecoxib | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | 16 |
| Mupirocin | Mupirocin | 32 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 23 |
| Torsemide | Torsemide | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 14 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 16 |
| Finasteride | Finasteride | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 13 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Rayaldee | Calcifediol | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $322.09 · 18 records | Lilly USA, LLC | JARDIANCE, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, VOQUEZNA, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error